Jan 28 (Reuters) - AstraZeneca Plc :
* Lynparza granted BTD in US for prostate cancer
* US FDA has granted breakthrough therapy designation (btd) for oral poly adp-ribose polymerase (parp) inhibitor Lynparza
* Decision to assign a BTD for Lynparza is based on results of toparp-a phase II trial
* Breakthrough therapy designation for Lynparza in this patient population means FDA will expedite review of submission data within 60 days of receipt Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)
Our Standards: The Thomson Reuters Trust Principles.